Equity
€574,229 ▲ 22.4%
OPHTACA has made a profit in every financial year since 2016.
OPHTACA
Lifetime
10 annual accounts with figures on one time axispeak €200,414 (2018)
€194,195▼ 1.5%
peak €132,790 (2019)
€105,179▼ 3.1%
peak €574,229 (2025)
€574,229▲ 22.4%
€69,797▼ 60.6%
peak 0.9 FTE (2020)
-not published
Board1 name since 2016
1 directorCASPERS Laure
Documentsfilings and deeds
29-08-202629 days late
2025micro format
Equity from €469,049 to €574,229Debts from €177,204 to €69,797Cash from €269,838 to €69,464
Key points
from the 2025 annual accountsChecked score
95
Excellent
Financially stronger than 58% of micro companies in human health (NACE 86)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: < 0.1% across 24,192 companies (NACE 86, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 0.1%
01-2025: 0.1%● unchanged vs 12-2024
02-2025: 0.1%● unchanged vs 01-2025
03-2025: 0.1%● unchanged vs 02-2025
04-2025: 0.1%● unchanged vs 03-2025
05-2025: 0.1%● unchanged vs 04-2025
06-2025: 0.1%● unchanged vs 05-2025
07-2025: 0.2%▲ +0.1 percentage points vs 06-2025
08-2025: 0.3%▲ +0.1 percentage points vs 07-2025
09-2025: 0.3%● unchanged vs 08-2025highest value
10-2025: < 0.1%▼ -0.3 percentage points vs 09-2025
11-2025: < 0.1%● unchanged vs 10-2025
12-2025: < 0.1%● unchanged vs 11-2025
01-2026: < 0.1%● unchanged vs 12-2025lowest value
02-2026: < 0.1%● unchanged vs 01-2026
03-2026: < 0.1%● unchanged vs 02-2026
04-2026: < 0.1%● unchanged vs 03-2026
05-2026: < 0.1%● unchanged vs 04-2026
06-2026: < 0.1%● unchanged vs 05-2026
07-2026: < 0.1%● unchanged vs 06-2026
08-2026: 0.1%▲ +0.1 percentage points vs 07-2026
09-2026: < 0.1%▼ -0.1 percentage points vs 08-2026
10-2026: < 0.1%● unchanged vs 09-2026
11-2026: < 0.1%● unchanged vs 10-2026
Financial strengthStrong
Score breakdown
raises risk
Last filed accounts filed 29 days late; 2 of the last 3 accounts late
lowers risk
Sector: Human health activities (NACE 86)
Size: total assets €644,026
Equity €574,229 (89.2% of total assets)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 86, micro). It does better than 82% of them on solvency, 41% on liquidity, 43% on profitability and 66% on growth.
The bankruptcy probability was computed on 10-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 34,693 companies had the same profile as OPHTACA has now. Each dot stands for 87 companies, two years later.
95.3%
were still trading
3.9%
stopped another way
0.7%
went bankrupt
That fits the bankruptcy probability of OPHTACA itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 34,693 companies, not a prediction for OPHTACA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €50,000 on 30-day terms is acceptable
Liquidity is ample, with a current ratio of 9.08 (3.57 in 2024), above the usual 1.5. Short-term debt is 10.8% and cash 10.8% of total assets. 10.8% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Five signals.
lowers riskraises risk
raises risk · 2025 accounts filed 29 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-08-2026, 29 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 10 filingsDeviation from the deadline
2025
29 days late
2024
54 days late
2023
69 days late
2022
32 days late
2021
31 days late
2020
60 days late
2019
47 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 46 days after the deadline. In the sector (NACE 86), the median for financial year 2024 was 7 days before the deadline, and 36% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 1 September (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
10-11-2026 today31-12-2026 year end31-07-2027 deadline
Recent changes
Reappointment: CASPERS Laure (director)
“La société a pour objet l’exercice de la médecine,et plus spécifiquement dans les techniques de…” (deed in French) · General meeting of 16-11-2023 · Gazette deed
Incorporation
published on 07-03-2016 · Gazette deed
First establishment
Gebladertelaan 11, Uccle
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| OPHTACA Uccle | €644,026 | €194,195 | 89.2% | - |
| Cabinet Médical Devresse Laure Liège | €689,437 | €197,626 | 77.0% | - |
| Dr. Colle Isabelle, gastro-enteroloog Wetteren | €635,632 | €198,525 | 76.4% | - |
| P & L MEDICAL Binche | €654,213 | €178,964 | 62.0% | - |
| Canseliet-Gillain Médecine physique et pédopsychiatrique Yvoir | €685,314 | €208,894 | 82.7% | - |
| MCF MEDICAL Fosses-la-Ville | €567,638 | €186,821 | 84.9% | - |
| Docteur Christophe ZIRAK Waterloo | €583,394 | €193,437 | 29.8% | - |
These companies have the same main activity as OPHTACA: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €568,000 and €689,000, founded between 2014 and 2016.
Official details
Source: KBO- Status
- Active since 03-03-2016Normal situation
- Activity
- Specialist medical practiceNACE 86220
- Establishment unit
- 2.250.978.6341180 Uccle, since 03-03-2016
- Financial year end
- 31 December
- Peppol
- Not found in the Peppol Directory
Annual accounts 2025
- ≈ €360,000estimated
- €644,026▼ 0.3%
- Employeeson 31-12-2025
- 2=
- Filing
- Filed on 29-08-2026
Insights on OPHTACA
OPHTACA files the micro format. That format states no turnover. The gross margin rose from €174,063 in 2016 to €194,195 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about OPHTACA
- What is the company number of OPHTACA?
- The company number of OPHTACA is 0649.583.264. The VAT number is the same number with BE in front: BE 0649.583.264.
- Where is OPHTACA based?
- The registered office is at Gebladertelaan 11, 1180 Uccle.Company details
- What does OPHTACA do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of OPHTACA?
- OPHTACA is a private limited company (BV).
- When was OPHTACA founded?
- OPHTACA was founded on 03-03-2016.
- Is OPHTACA still active?
- Yes, OPHTACA is an active enterprise in the KBO register.
- How many employees does OPHTACA have?
- OPHTACA had an average of 2 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of OPHTACA?
- The turnover in financial year 2025 is ≈ €360,000. This figure is estimated from the gross margin of €194,195 and 41 comparable companies (NACE 86220). It probably lies between €310,000 and €480,000.
- Is OPHTACA profitable?
- In financial year 2025, OPHTACA made a profit of €105,179.
- Where can I find the annual accounts of OPHTACA?
- OPHTACA filed 10 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of OPHTACA due?
- OPHTACA must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.